Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.18 USD

41.18
3,306,805

+0.86 (2.13%)

Updated Aug 13, 2024 04:00 PM ET

Pre-Market: $41.06 -0.12 (-0.29%) 9:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

by Zacks Equity Research

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas

by Zacks Equity Research

Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Glaxo (GSK) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Glaxo (GSK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential

by Zacks Equity Research

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?

by Zacks Equity Research

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy

by Zacks Equity Research

The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.

Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year

by Zacks Equity Research

Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.

Here's Why You Should Add Omnicell (OMCL) To Your Portfolio

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its better-than-expected results in the third quarter and robust segmental performance.

Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus

by Zacks Equity Research

Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.

Best Income Stocks to Buy for November 22nd

by Zacks Equity Research

SPH, XOM, GSK, and FFIC made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 22, 2021.

Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion

by Zacks Equity Research

Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.

Gilead (GILD) Exercises Options to Three Arcus Programs

by Zacks Equity Research

Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).

LabCorp (LH) to Expand Nonclinical Development With New Buyout

by Zacks Equity Research

LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.

Pfizer (PFE) Inks $5.3B COVID Pill Supply Deal With U.S.

by Zacks Equity Research

The U.S. government is set to purchase 10 million treatment courses of Pfizer's (PFE) oral pill for COVID-19, Paxlovid, if approved or authorized.

AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU

by Zacks Equity Research

AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.

Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU

by Zacks Equity Research

Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine. Evidently, the stock gains.

Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings

by Zacks Equity Research

The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.

Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government

by Zacks Equity Research

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Spin Off Consumer Unit, PFE Eyes EUA for COVID Pill

by Kinjel Shah

J&J (JNJ) decides to split into two companies. Pfizer (PFE) seeks nod for emergency use of COVID antiviral pill. Glaxo's (GSK) and AbbVie's (ABBV) drugs get approvals in new indications.

GSK or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. NVO: Which Stock Is the Better Value Option?

Abbott (ABT) Introduces New Next-Generation Infant Formula

by Zacks Equity Research

Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.

4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio

by Zacks Equity Research

Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term

AstraZeneca (AZN), Moderna's Heart Failure Study Successful

by Zacks Equity Research

AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.